TNF and rheumatoid arthritis: Adalimumab (ADM), a fully human monoclonal antibody that neutralizes tumor necrosis factor-α (TNF-α), was initially approved for the treatment of moderate to severe rheumatoid arthritis (RA) in 2002 (Rau, 2002).